The drugs are likely to cost 50-95% less than their private branded counterparts & the medicines include cardiovascular, diabetes, respirat...

“If we allowed one such player with a significant market share to withdraw, we cannot stop other such players from doing it.

The two drugmakers declined to confirm the development, even as the news sent market punters to bet on the likely impact on its Indian subs...

Conventional wisdom suggests that healthcare sector is recession proof and does not necessarily mirror the lows and highs of the economy.

In a shocking representation of the lack of essential healthcare, the largest chunk of doctors in the country do not hold the MBBS degree.

The average doctor ratio per 1,000 population is 1.1 in 120 cities surveyed by IMS, which covered nearly three lakh doctors.

Urban residents, who form only 28 per cent of India's population, get the lion's share when it comes to access to hospital beds.

The new drug price control policy is likely to be a boon for consumers as it will put an end to the "arbitrary" pricing regime.

The just-notified new drug price control policy will negatively impact sales and margins of pharmaceutical firms in India, according to ind...

Analysts said the new norms will adversely impact multinational companies as well as local firms producing essential drugs.

The 72,000-crore domestic drug market could grow between 11% and 13% in 2013, according to projections by pharma market research firms.

The firm that was largely a provider of sales data to pharmaceutical companies until now, will roll out a census of hospitals, doctors and ...

The Indian market is now among the top five pharmaceutical emerging, or ‘pharmerging’ , markets.

A govt panel will recommend fixing retail prices of 348 drugs at weighted average price of brands with over 1% market share.

Indian and foreign drug makers have already suffered heavy revenue loss due to changes in drug pricing or procurement policies in countries...

Drug firms can offset the impact if they raise prices of brands currently sold below their proposed ceilings.